Pharmaceutical composition for treating neuroblastoma

The combination of edanilic acid and quizatinib, combined with doxorubicin or cisplatin, significantly inhibits the growth of neuroblastoma, solves the problem of poor treatment effect of neuroblastoma in the high-risk group and improves the treatment Effects and survival rates enhance anti-tumor activity.

CN118924724AActive Publication Date: 2024-11-12HUNAN UNIV +1

Patent Information

Application Number
CN202411021365.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-12
Estimated Expiration
2044-07-29

AI Technical Summary

Technical Problem

The therapeutic effect of neuroblastoma in high-risk groups and the tolerance level of patients are close to the maximum. The therapeutic effect and survival rate of traditional chemotherapy regimens on neuroblastoma are low, especially in the high-risk groups, and the surgical treatment effect is limited, and molecular targeting Drugs such as quizatinib are not effective in preclinical animal experiments.

Method used

Using pharmaceutical compositions of etanyl acid and quizatinib, combined with doxorubicin or cisplatin, significantly inhibit the proliferation of neuroblasts and induce cell death, enhance anti-tumor activity, and utilize mitochondria. Autophagy activity synergistically induces tumor cell death.

Benefits of technology

It significantly inhibits the growth of neuroblastoma in vitro and in vivo, improves the therapeutic effect, enhances the anti-tumor activity of quizatinib, significantly induces neuroblast death, and improves the survival rate and quality of life of patients in high-risk groups.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924724A_ABST
    Figure CN118924724A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly discloses a pharmaceutical composition for treating neuroblastoma, which comprises ethacrynic acid, or a precursor of ethacrynic acid, or a pharmaceutically acceptable salt of ethacrynic acid, or a pharmaceutically acceptable carrier of ethacrynic acid. The pharmaceutical composition also comprises an anti-tumor drug, or a precursor of the anti-tumor drug, or a pharmaceutically acceptable salt of the anti-tumor drug, or a pharmaceutically acceptable carrier of the anti-tumor drug. The antitumor drug is quatitinib, doxorubicin or cis-platinum. The pharmaceutical composition provided by the invention not only can significantly induce death of neuroblasts SH-SY5Y and SK-N-B2 in vitro to enhance the antitumor activity of the quinatinib, but also can significantly inhibit growth of subcutaneous transplanted tumors of nude mice with neuroblasts in vivo, and can induce death of transplanted tumor cells; and the enhanced autophagy activity plays an important role in neuroblastoma death synergistically induced by the combination of the quinatinib and the ethacrynic acid.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a pharmaceutical composition for treating neuroblastoma. Background Art

[0002] Neuroblastoma (NB) is different from most other tumors in that it is more common in children. It is an embryonic tumor originating from the neural crest and is composed of undifferentiated sympathetic nerve cells. The incidence rate is about 1 / 100,000 in children under 15 years old. It is the most common malignant tumor in children under 1 year old. Due to the improvement of diagnostic methods and treatment methods for neuroblastoma in recent years, the overall survival rate of neuroblastoma patients has been greatly improved, but the survival rate and quality of life of high-risk children have not been significantly improved.

[0003] Clinically, neuroblastoma is divided into low-risk group, intermediate-risk group and high-risk group. The high-risk group refers to clinical stage 4, age > 1 year old; or clinical stage 3, > 1 year old, Shimada poor prognosis type, MYCN gene amplification or elevated serum ferritin; or clinical stage 3, 4, 4S, any age + MYCN amplification; or clinical stage 1, 2, age > 1 year old + MYCN amplification. Due to the high malignancy of the high-risk group, early bone marrow and / or bone metastasis, and the presence of minimal residual disease (MRD), the effect of surgical treatment is very limited. At present, the therapeutic effect of traditional chemotherapy regimens on neuroblastoma and the tolerance of patients have reached the maximum limit. The alternating chemotherapy regimen of CiE (cisplatin + etoposide) and CDV (cyclophosphamide + daunorubicin + vincristine) is currently the first-line chemotherapy regimen for high-risk neuroblastoma, but the complete remission (CR) and very good partial remission (VGPR) are still less than 40%.

[0004] Currently, exploring more effective medication regimens based on molecular targeted drugs is an urgent task for the treatment of high-risk neuroblastoma, in order to enhance the treatment effect and cure rate and improve the quality of life of clinical children. Summary of the invention

[0005] The purpose of the present invention is to provide a pharmaceutical composition for treating neuroblastoma to solve the above technical problems.

[0006] One aspect of the present invention relates to a pharmaceutical composition for treating neuroblastoma, comprising ethacrynic acid, or a precursor of ethacrynic acid, or a pharmaceutically acceptable salt of ethacrynic acid, or a pharmaceutically acceptable carrier of ethacrynic acid; and also comprising an anti-tumor drug, or a precursor of the anti-tumor drug, or a pharmaceutically acceptable salt of the anti-tumor drug, or a pharmaceutically acceptable carrier of the anti-tumor drug; the anti-tumor drug is quizartinib, doxorubicin or cisplatin.

[0007] In the present invention, ethacrynic acid (EA), also known as ethacrynic acid, is an organic compound with CAS NO: 58-54-8 and a chemical formula of C 13 H 12 Cl2O4 is a diuretic, mainly used for congestive heart failure, acute pulmonary edema, renal edema, cirrhosis ascites, liver cancer ascites, schistosomiasis ascites, cerebral edema and other edema diseases, and can relieve edema symptoms caused by heart failure and renal failure. However, there is no record of using ethacrynic acid for the treatment of neuroblastoma.

[0008] The molecular formula of Quizartinib (AC220) is C 29 H 32 N6O4S, molecular weight 560.7, CAS No. 950769-58-1, inhibits autophosphorylation of wild-type FLT3 and mutant FLT3 ITD, and is an orally active, highly selective, and effective second-generation type II FLT3 tyrosine kinase inhibitor. Quizartinib can significantly inhibit the proliferation of some tumor cells, but the proliferation inhibition effect of quizartinib mainly depends on its significant cycle arrest effect and cannot effectively induce tumor cell death. Therefore, the effect of quizartinib in preclinical animal experiments is not ideal.

[0009] The pharmaceutical composition provided by the present invention can be prepared into any conventional preparation form by conventional methods. The dosage form can be various, as long as it is a dosage form that can effectively allow the active ingredient to reach the body of a mammal. For example, it can be selected from: injection, infusion, tablet, capsule, pill. Wherein ethacrynic acid or quizartinib can be present in a suitable solid or liquid carrier or diluent.

[0010] Ethacrynic acid and quizartinib can be administered orally and intravenously, intramuscularly or subcutaneously, respectively, or after Ethacrynic acid and quizartinib are mixed, they are administered orally and intravenously, intramuscularly or subcutaneously. The drug forms adapted for injection include: sterile aqueous solutions or dispersions and sterile powders (for temporary preparation of sterile injection solutions or dispersions). In all cases, these forms must be sterile and must be fluids to facilitate the discharge of fluids from syringes. It must be stable under manufacturing and storage conditions, and must be able to prevent the contamination effects of microorganisms (such as bacteria and fungi). The carrier can be a solvent or a dispersion medium, which contains, for example, water, alcohol (such as glycerol, propylene glycol and liquid polyethylene glycol), their appropriate combinations and vegetable oils.

[0011] When necessary, ethacrynic acid and quizartinib can be administered in combination with other active ingredients or drugs.

[0012] After long-term and extensive research, the present invention unexpectedly found that the combined use of ethacrynic acid and quizartinib has an excellent effect on the treatment of neuroblastoma.

[0013] In the specific embodiments of the present invention, some compositions of ethacrynic acid and quizartinib are provided. For example, in one embodiment, in an animal experiment on mice, a dosage regimen of ethacrynic acid and quizartinib in a weight ratio of 5:3 is proposed, specifically, ethacrynic acid 5 mg / kg, quizartinib 3 mg / kg.

[0014] Another aspect of the present invention relates to the use of a pharmaceutical composition of ethacrynic acid and quizartinib in the treatment of neuroblastoma.

[0015] Another aspect of the present invention relates to the use of a pharmaceutical composition of ethacrynic acid and doxorubicin in treating neuroblastoma.

[0016] Another aspect of the present invention relates to the use of a pharmaceutical composition of ethacrynic acid and cisplatin in treating neuroblastoma.

[0017] The present invention combines it with various natural compounds to screen out substances that can cooperate with each other to enhance the anti-tumor effect. Cell experiments have shown that AC220 combined with doxorubicin and AC220 combined with Cisplatin can significantly inhibit the proliferation of SH-SY5Y cells. After a large amount of screening work, it was found that the combined treatment of neuroblastoma with ethacrynic acid and quizartinib can not only significantly induce the death of SH-SY5Y and SK-N-B2 neuroblastoma cells in vitro, enhance the anti-tumor activity of quizartinib, but also significantly inhibit the growth of neuroblastoma in situ transplanted tumors in vivo, and induce the death of transplanted tumor cells, and the inhibition of mitochondrial autophagy activity plays an important role in the death of neuroblastoma synergistically induced by quizartinib combined with ethacrynic acid. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 The graph shows the inhibitory effect of the AC220+EA combination group on SH-SY5Y cell proliferation; A: SH-SY5Y cells treated with DMSO for 24 hours; B: SH-SY5Y cells treated with 75μM EA for 24 hours; C: SH-SY5Y cells treated with 10μM AC220 for 24 hours; D: SH-SY5Y cells pretreated with 10μM AC220 for 2 hours and then treated with 75μM EA for 24 hours.

[0019] Figure 2 Figure 1 is a flow cytometric statistical graph of PI uptake.

[0020] Figure 3 This is a statistical diagram of flow cytometry detection of mitochondrial ROS.

[0021] Figure 4 This is the result of SH-SY5Y cell pyroptosis induced by the AC220+EA combination group.

[0022] Figure 5 This is an image taken by the small animal in vivo imaging system on the 27th day after tumor transplantation.

[0023] Figure 6 The images of mouse ex vivo tumor tissues on the 30th day after tumor transplantation. A: Control group: Saline group tumors, mice in this group were injected with control solvent every day after tumor transplantation; B: Experimental group 1: AC220 group, mice in this group were injected with 3mg / kg AC220 every day after tumor transplantation; C: Experimental group 2: EA group, mice in this group were injected with 5mg / kg EA every day after tumor transplantation; D: Experimental group 3: EA+AC220 group, mice in this group were injected with 3mg / kg AC220 and 5mg / kg EA every day after tumor transplantation.

[0024] Figure 7 The figure is a statistical graph of tumor weight.

[0025] Figure 8 Figure 3 shows the weight changes of mice after tumor transplantation.

[0026] Fig. 9 This is the result of Ki67 staining of tumor tissue sections.

[0027] Fig.10 This is the result of Cleaved-caspase3 staining in tumor tissue sections.

[0028] Fig.11 The AC220+doxorubicin combination group has an inhibitory effect on SH-SY5Y cell proliferation. A: SH-SY5Y cells treated with DMSO for 24 hours; B: SH-SY5Y cells treated with 2.5μM doxorubicin for 24 hours; C: SH-SY5Y cells treated with 10μM AC220 for 24 hours; D: SH-SY5Y cells pretreated with 10μM AC220 for 2 hours and then treated with 2.5μM doxorubicin for 24 hours.

[0029] Fig.12 The AC220+Cisplatin combination group has an inhibitory effect on SH-SY5Y cell proliferation. A: SH-SY5Y cells treated with DMSO for 24 hours; B: SH-SY5Y cells treated with 10μM Cisplatin for 24 hours; C: SH-SY5Y cells treated with 10μM AC220 for 24 hours; D: SH-SY5Y cells pretreated with 10μM AC220 for 2 hours and then treated with 10μM Cisplatin for 24 hours. DETAILED DESCRIPTION

[0030] The following is further described in detail through specific implementation methods:

[0031] 1. Cell experiments

[0032] 1. Cell culture

[0033] The human neuroblastoma cell line SH-SY5Y was purchased from the American Type Culture Collection (ATCC). SH-SY5Y was cultured in DMEM high-glucose medium (purchased from Wuhan Pronocell Life Science Co., Ltd.), with the addition of 10% fetal bovine serum (purchased from OriCell) and 1% penicillin-streptomycin (purchased from Suzhou Xinsaimei Biotechnology Co., Ltd.). The cells were cultured in 6-well plates, with 1.5 mL of culture medium per well, at 37°C, in a 5% CO2 saturated humidity incubator. AC220 and EA were dissolved in DMSO for use, and after appropriate aliquoting, they were stored at -20°C in the dark.

[0034] 2. Drug treatment

[0035] Dissolve AC220 in DMSO to prepare a stock solution with a final concentration of 10 mM, and aliquot for later use. Dissolve EA in DMSO to prepare a stock solution with a final concentration of 75 mM, and aliquot for later use. Store at -80°C in the dark.

[0036] When the cell density reaches 60-70%, it is ready to add drugs.

[0037] Experimental groups: DMSO group, EA group, AC220 group and AC220+EA combined group.

[0038] The AC220+EA combination group pretreated SH-SY5Y cells with 10μM AC220 for 2 hours, and then each group was treated with DMSO, AC220 10μM, EA75μM and 10μM AC220 combined with 75μM EA, respectively. After 24 hours, the proliferation inhibitory effect of each group of drugs on the human neuroblastoma cell line SH-SY5Y was observed.

[0039] Figure 1 The AC220+EA combination group has an inhibitory effect on SH-SY5Y cell proliferation. A: SH-SY5Y cells treated with DMSO for 24 hours; B: SH-SY5Y cells treated with 75μM EA for 24 hours; C: SH-SY5Y cells treated with 10μM AC220 for 24 hours; D: SH-SY5Y cells pretreated with 10μM AC220 for 2 hours and then treated with 75μM EA for 24 hours. Figure 1 As shown, it can be observed that compared with other groups, the AC220+EA combination group can significantly inhibit the proliferation of SH-SY5Y cells.

[0040] 3. PI uptake detection

[0041] (1) Digest and collect the cells after treatment in (ii). The culture supernatant is placed in a 5mL EP tube. Wash the cells twice with 0.5mL of 4℃ precooled PBS buffer. After washing, transfer the PBS to the corresponding EP tube. Then add 0.5mL of EDTA-free trypsin to each well and place it in a 37℃ constant temperature incubator for digestion for 5min. Gently blow the cells off and transfer them to the corresponding EP tube to terminate digestion. Then wash the well plate again with 0.5mL PBS and transfer it to the corresponding EP tube. Centrifuge at 1000rpm for 5min at 4℃. Discard the supernatant, then quickly add 1mL of precooled PBS to the EP tube to wash the cell pellet, and gently blow several times to mix. Centrifuge at 1000rpm for 5min at 4℃. Repeat this step once. Obtain single suspended cells.

[0042] (2) Take 1000 μL PBS and add 3 μL PI dye (the kit was purchased from Bio-Tech Biosciences, ST511). Resuspend the washed cells with 100 μL diluted PI dye, filter with a 200-mesh filter, transfer to a flow cytometer, store on ice in the dark, and then perform detection on a flow cytometer (BD Biosciences, FACSCelesta) at 561 nm channel, and record the PI positive ratio, which is the dead cell ratio.

[0043] Figure 2 Figure 1 is a flow cytometry analysis of PI uptake. Figure 2 As shown, compared with the other groups, it can be observed that the PI uptake in the AC220+EA combination group was significantly increased, indicating that compared with the other groups, the AC220+EA combination group was more lethal to SH-SY5Y.

[0044] 4. mitoROS detection

[0045] Take the cells treated with drugs in (ii), digest and wash them in the same way as in (iii) (1) to obtain single suspended cells. Take 1000 μL PBS, add 0.5 μL MitoSOX (M36008, Invitrogen) storage solution to it, and make the final concentration of the dye solution 1 μM. Resuspend the washed cells with 100 μL diluted MitoSOX dye, then filter with a 200-mesh filter and transfer to a flow tube, temporarily store on ice away from light, and then perform detection on the 561 nm channel of a flow cytometer (BD Biosciences, FACSCelesta), and record the MitoSOX positive ratio.

[0046] Figure 3 Figure 2 is a flow cytometry statistical diagram of mitochondrial ROS. Figure 3 As shown, it can be observed that the production of mitoROS in the combined group increased significantly, indicating an increase in mitochondrial reactive oxygen species.

[0047] 5. Expression detection of pyroptosis executive protein GSDME

[0048] Take the cells treated with drugs (II) for Western Blot, the specific operation is as follows:

[0049] (1) Sample preparation: Wash the treated cells twice with cold PBS, remove the culture medium, and then add an appropriate amount of protein lysis buffer according to the cell volume. Collect the cells into a 1.5 mL centrifuge tube, heat them in a 100°C metal bath for 10 min, and remove the precipitate by centrifugation. Add 5× loading buffer and heat them in a 100°C metal bath for 5 min. The sample is then prepared.

[0050] (2) SDS-PAGE electrophoresis: Prepare 10% separation gel and 5% concentration gel, use 1.5 mm glass plate and comb. Load the sample after the gel is completely solidified. The electrophoresis parameters for the upper gel are constant voltage 80V, 30min, and the electrophoresis parameters for the lower gel are constant voltage 120V, 80min. Stop the electrophoresis when the bromophenol blue band approaches the lower end of the gel.

[0051] (3) Transfer: Prepare a PVDF membrane of appropriate size, activate it with anhydrous methanol, place both the gel and PVDF membrane in the pre-cooled transfer solution, stack them from the negative electrode to the positive electrode in the order of sponge-filter paper-gel-PVDF membrane-filter paper-sponge, and place them in the transfer device to ensure that there are no bubbles between each layer. Place the transfer system in an ice bath, use a constant current of 400 mA, and transfer for 90 minutes.

[0052] (4) Blocking: After the transfer is completed, take out the PVDF membrane with the front side facing up, put it into 5% skim milk prepared with TBST, and incubate it on a shaker for 1 hour.

[0053] (5) Antibody incubation: After blocking, place the PVDF membrane on a shaker and rinse it with TBST three times, 10 min each time. After washing, add GSDME antibody and incubate it on a shaker at 4°C overnight. The next day, recover the antibody and rinse it with TBST three times, 10 min each time. Then add the corresponding secondary antibody, place it on a shaker, and incubate it at room temperature for 1 hour. Then recover the secondary antibody and add TBST to rinse it three times, 10 min each time.

[0054] (6) On-machine development: Mix the developer reagent A and reagent B in a ratio of 1:1 and drop them onto the PVDF membrane. Use a coating rod to evenly spread the developer to allow for full reaction. Then place the membrane in a chemiluminescence instrument for detection and recording.

[0055] Figure 4 The results of SH-SY5Y cell pyroptosis induced by AC220+EA combination group. Figure 4 As shown, GSDME cleavage in other groups was not obvious, while GSDME cleavage in the combined group increased significantly, indicating that AC220+EA combined group treatment promoted GSDME cleavage, thereby promoting cell pyroptosis.

[0056] 6. Other anticancer drugs combined with AC220 to treat SH-SY5Y

[0057] The cell-treated AC220 was dissolved in DMSO to prepare a storage solution with a final concentration of 10mM, which was then divided into portions for use. Cisplatin was dissolved in sterile water to prepare a storage solution of 1mg / mL, which was then divided into portions for use. Doxorubicin was dissolved in DMSO to prepare a 5mM storage solution, which was stored at 4°C in the dark. After SH-SY5Y cells were pretreated with 10μMAC220 for 2h, they were treated with DMSO, doxorubicin 2.5μM (or Cisplatin 10μM), AC220 10μM, and 10μMAC220+doxorubicin combined group 2.5μM (or Cisplatin 10μM), and the proliferation inhibitory effect of each group of drugs on SH-SY5Y cells was observed after 24h.

[0058] Fig.11 The AC220+doxorubicin combination group has an inhibitory effect on SH-SY5Y cell proliferation. A: SH-SY5Y cells treated with DMSO for 24 hours; B: SH-SY5Y cells treated with 2.5μM doxorubicin for 24 hours; C: SH-SY5Y cells treated with 10μM AC220 for 24 hours; D: SH-SY5Y cells pretreated with 10μM AC220 for 2 hours and then treated with 2.5μM doxorubicin for 24 hours. Fig.12 This is the effect diagram of the AC220+Cisplatin combination group on the inhibition of SH-SY5Y cell proliferation. Fig.12 A is SH-SY5Y cells treated with DMSO for 24 hours. Fig.12 B is SH-SY5Y cells treated with 10 μM Cisplatin for 24 h. Fig.12 C is SH-SY5Y cells treated with 10 μM A220 for 24 h. Fig.12 D is SH-SY5Y cells pretreated with 10 μM A220 for 2 h and then treated with 10 μM Cisplatin for 24 h.

[0059] like Fig.11 , Fig.12As shown, it can be observed that the AC220+doxorubicin combination group 2.5 μM (or Cisplatin 10 μM) significantly inhibited the proliferation of SH-SY5Y cells.

[0060] 2. Animal Experiments

[0061] 1. Construction of Luciferase-labeled neuroblastoma cell line SH-SY5Y

[0062] (1) Take 6×10 4 SH-SY5Y cells growing in logarithmic phase were resuspended in serum-free and dual antibody-free medium, inoculated into 96-well plates, and 10 μL of 1×10 8 TU / mL of EF1a-mCherry-Luc Lentivirus (Jiman Biotechnology, GM-0220IV208). Change the medium 16 hours after transfection, and change the medium every two days. When the cells grow to 90%, they are passaged. After the cells are transferred to a 10 cm culture dish, the cells are collected for flow cytometry sorting, and the cells with mCherry labels are screened out, which are the cells that are successfully infected and recorded as SH-SY5Y-Luc.

[0063] (2) 5-7×10 6 Each SH-SY5Y-Luc cell was cultured in a 10 cm dish using DMEM medium containing 10% fetal bovine serum and 0.1 mg / ml penicillin-streptomycin.

[0064] 2. In situ injection of SH-SY5Y-Luc cells into mouse adrenal glands

[0065] (1) Aliquot the matrix gel and thaw it in an ice box at 4°C for 24 hours in advance. Aliquot PBS and pre-cool it separately. Pre-cool the autoclaved 1.5mL centrifuge tubes, 1mL pipette tips, 200μL pipette tips, and insulin syringes at -20°C. Change the cell medium one day in advance.

[0066] (2) On the day of tumor inoculation, prepare an ice box and irradiate the cells with UV light for 30 minutes in advance. Keep the matrix gel on ice throughout the process. Digest the cells with a density of 80-90% with trypsin, wash twice with 4°C PBS, and resuspend the cells in 1 mL PBS for counting. Dilute the matrix gel with cold PBS in a ratio of 1:1 and place the cells at a density of 1×10 7 / mL of cells were resuspended in 2mL PBS-Matrigel suspension. The resuspended cells were divided into 5 tubes and placed on ice.

[0067] (3) NCG mice (purchased from Saiye Biotechnology Co., Ltd.) were weighed and anesthetized. After the anesthesia of the mice was stable, surgery was performed. The hair on the right side of the mouse's back was shaved and disinfected with alcohol. An opening was made at the lower edge of the right rib on the back to avoid excessive bleeding and expose the adrenal gland. Forceps were used to open the incision to expose the injection area. An insulin needle was used to absorb the inverted and mixed cell suspension, and 0.02 mL was injected into each mouse. After the injection, the syringe was suspended for a few seconds to ensure that the injection was successful and there was no leakage. After the injection, 4-0 sutures were used to suture the muscle layer and skin layer, and appropriate antibiotics were added, and the mice were placed back in a clean cage. This is day 0 of tumor inoculation.

[0068] (4) Three days after tumor inoculation, live imaging of mice was performed. The operation process was as follows: 0.1 mL, 20 mg / ml of luciferase substrate D-luciferin potassium salt (D-Luciferin potassium salt) was injected intraperitoneally into the mouse. After 7 minutes, the anesthetized mouse was placed in the PE LμMina III (purchased from PerkinElmer) imaging system for imaging.

[0069] Randomly divided into 4 groups:

[0070] Control group, experimental group 1, experimental group 2 and experimental group 3.

[0071] Control group: Saline tumor group, mice in this group were injected with blank solvent every day after tumor transplantation.

[0072] Experimental group 1: AC220 group, mice in this group were injected with 3 mg / kg AC220 per day after tumor transplantation.

[0073] Experimental group 2: EA group, each mouse in this group was injected with 5 mg / kg EA every day after tumor transplantation.

[0074] Experimental group 3: EA+AC220 group (combination group), each mouse in this group was injected with 3 mg / kg AC220 and 5 mg / kg EA every day after tumor transplantation.

[0075] The mice were dosed after grouping, which was recorded as the first day of drug administration. Thereafter, the mice were dosed every day and weighed.

[0076] Figure 8 Figure 2 is a graph showing the weight changes of mice after tumor transplantation. Figure 8 As shown, there was no significant difference among the groups, and images were taken on days 3, 6, 9, 12, 15, 18, 21, 24, and 27 of administration to record the changes in the tumor.

[0077] Figure 5 This is an image of the small animal in vivo imaging system on the 27th day after tumor transplantation. Figure 5As shown, the tumor size in the EA+AC220 combination group was significantly smaller than that in the other three groups.

[0078] (5) On the 30th day after administration, mice were killed by cervical dislocation and kidney and tumor tissues were obtained. Figure 6 As shown, Figure 6 A is the control group: the Saline group of mice, which were injected with blank solvent every day after tumor transplantation. Figure 6 B is experimental group 1: the AC220 group. Each mouse in this group was injected with 3 mg / kg AC220 every day after tumor transplantation. Figure 6 C is experimental group 2: EA group, in which mice were injected with 5 mg / kg EA every day after tumor transplantation. Figure 6 D is experimental group 3: EA+AC220 group. After tumor transplantation, mice in this group were injected with 3mg / kg AC220 and 5mg / kg EA every day. The tumor tissue was separated from the kidney tissue and weighed. The results are as follows: Figure 7 As shown, the tumor tissue volume and weight were significantly inhibited in the EA+AC220 group after administration.

[0079] (6) The tumor tissues after peeling were taken and fixed, dehydrated, waxed and embedded in groups. The intact tissues were cut into 4-6 micron thickness using a slicer. Then the steps of dewaxing and rehydration, antigen repair, removal of endogenous peroxidase, blocking and antibody incubation, secondary and tertiary antibody incubation, and color development were carried out in sequence. Immunohistochemical detection of Ki67 and cleaved-caspase3 expression in the tissues was performed.

[0080] Fig. 9 This is the result of Ki67 staining of tumor tissue sections. Fig.10 This is the result of Cleaved-caspase3 staining in tumor tissue sections. Fig. 9 and Fig.10 As shown, the results showed that the expression of Ki67 in tissues decreased and the expression of Cleaved-caspase3 increased in the AC220+EA combination group.

[0081] In summary, cell experiments have shown that AC220 combined with doxorubicin and AC220 combined with Cisplatin can significantly inhibit the proliferation of SH-SY5Y cells. Cell experiments and animal experiments have shown that the combined treatment of neuroblastoma with ethacrynic acid and quizartinib can not only significantly induce the death of SH-SY5Y and SK-N-B2 neuroblastoma cells in vitro and enhance the anti-tumor activity of quizartinib, but also significantly inhibit the growth of subcutaneous transplanted tumors of neuroblastoma nude mice in vivo and induce the death of transplanted tumor cells. The enhanced autophagic activity plays an important role in the death of neuroblastoma cells synergistically induced by quizartinib combined with ethacrynic acid.

[0082] The preferred specific embodiments of the present invention are described in detail above. It should be understood that a person skilled in the art can make many modifications and changes based on the concept of the present invention without creative work. Therefore, any technical solution that can be obtained by a person skilled in the art through logical analysis, reasoning or limited experiments based on the concept of the present invention on the basis of the prior art should be within the scope of protection determined by the claims.

Claims

1. A pharmaceutical composition for treating neuroblastoma, It is characterized in that It includes ethacrynic acid, or a precursor of ethacrynic acid, or a pharmaceutically acceptable salt of ethacrynic acid, or a pharmaceutically acceptable carrier of ethacrynic acid; it also includes an anti-tumor drug, or a precursor of an anti-tumor drug, or a pharmaceutically acceptable salt of an anti-tumor drug, or a pharmaceutically acceptable carrier of an anti-tumor drug; the anti-tumor drug is quizartinib, doxorubicin or cisplatin.

2. The pharmaceutical composition for treating neuroblastoma according to claim 1, It is characterized in that Ethacrynic acid 5mg / kg, quizartinib 3mg / kg.

3. Use of the pharmaceutical composition of ethacrynic acid and quizartinib in the treatment of neuroblastoma.

4. Use of a pharmaceutical composition of ethacrynic acid and doxorubicin in the treatment of neuroblastoma.

5. Use of a pharmaceutical composition of ethacrynic acid and cisplatin in the treatment of neuroblastoma.

Citation Information

Patent Citations

  • Medical application of bilobalide composition

    CN107929282A

  • Anti-FLT3 antibodies and compositions

    CN115715297A

  • Discovery and application of pentalactone GSTs targeted natural inhibitor

    CN116270664A

  • Personalized starvation therapy for cancer

    WO2023108146A1

  • TDP-43 interference peptides, methods, and uses thereof

    WO2023130187A1

Cited By

  • Application of combined use of NK cell and GD2 antibody in preparation of medicine for treating neuroblastoma

    CN120241999A